BA
IONS icon

Boston Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Boston Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,875
Closed -$349K – 651
2017
Q3 		$349K Buy
6,875
+915
+15% +$47.9K 0.01% 559
2017
Q2 		$303K Sell
5,960
-2,840
-32% -$132K 0.01% 575
2017
Q1 		$354K Buy
+8,800
New +$395K 0.01% 535
2015
Q2 		– Sell
-8,310
Closed -$529K – 668
2015
Q1 		$529K Buy
8,310
+4,500
+118% +$305K 0.02% 450
2014
Q4 		$235K Buy
+3,810
New +$188K 0.01% 534

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Boston Advisors's IONS Position: Q4 2017 in Review

Boston Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 6,875 shares — an estimated $349K sold.

Boston Advisors first reported a position in IONS in Q4 2014 and held it in 5 quarters. The position peaked at $529K in Q1 2015. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

  • Boston Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Boston Advisors sold 6,875 Ionis Pharmaceuticals shares in Q4 2017, an estimated $349K.
  • Boston Advisors first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Boston Advisors's Ionis Pharmaceuticals position peaked at $529K in Q1 2015.
  • 316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Boston Advisors's 13F filing for Q4 2017, filed 24 Jan 2018.